Latest fund size
$200M
Announced
October 2, 2026
Global HQ
United States
Members only
Check size
$1M - $15M
Members only
Stage focus
Seed, Series A, Series B, Growth (Series C+)
Members only
Regions of investment
North America
Members only
Hatteras Venture Partners is a Durham, North Carolina–based venture capital firm founded in 2000 that invests in seed and early-stage companies in human medicine. The firm focuses on biopharmaceuticals, medical devices, and health technology, with a long-standing reputation for backing transformative healthcare innovations. Hatteras is a Registered Investment Adviser (RIA) and manages more than $900 million across seven venture funds.
John Crumpler - General Partner
john@hatterasvp.com
Douglas Reed - General Partner
doug@hatterasvp.com
Heather Madsen - Venture Partner
heather@hatterasvp.com
Ben Scruggs - Partner
ben@hatterasvp.com
Christy Shaffer - General Partner
christy@hatterasvp.com
Graham Smith - Venture Partner
graham@hatterasvp.com
Members only
Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.
Hatteras targets early-stage investment opportunities in biopharmaceuticals, medical devices, and health technology, with an emphasis on companies that address significant unmet medical needs in human health.
Its portfolio spans therapeutics, diagnostics, medical tools, and healthcare technology solutions.
Members only
What the fund looks for in founders and which sectors it backs.
In August 2025, Hatteras Venture Partners announced the close of over $200 million across two new healthcare-focused funds: Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I (HOF I).
The capital was raised from a network of institutional limited partners and family offices.
HVP VII continues the firm’s focus on seed and early-stage investments, while HOF I is structured to pursue unique opportunities across the healthcare spectrum.
These funds expand Hatteras’s capacity to support innovative companies at multiple points in their development, from inception through growth stages.
In September 2026, Hatteras relaunched Hatteras Discovery & Innovation (HDI), a seed-stage company-formation initiative that evaluates promising academic and industry discoveries and accelerates their development, modeled on the firm's original 2012 Discovery program, which seeded 11 companies and produced two FDA-approved medicines, Cosela® and Xipere®.
The firm also announced a first closing of Hatteras Opportunity Fund II (HOF II), targeting $100 million in commitments for concentrated follow-on investments in portfolio companies approaching clinical, regulatory, and commercial milestones, building on HOF I's early positions in HistoSonics and Perfuse Therapeutics.
Members only
Fund size, LPs and track record.
Leadership
The firm is led by General Partners Clay Thorp and John Crumpler, supported by a team of experienced investors and sector specialists.
Recent promotions include Ben Scruggs, Ph.D., elevated from Principal to Partner with a focus on biopharmaceuticals and tools investments, and Lauren Flickinger, promoted to Partner and Fund Manager of the Pisgah Fund, who is also a leader in building the health technology portfolio.
In September 2026, Hatteras named Sir Andrew Witty, former CEO of GlaxoSmithKline and UnitedHealth Group and a Hatteras Venture Partner from 2017 to 2019, as Chairman, and Norman "Ned" Sharpless, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the U.S. Food and Drug Administration and co-founder of G1 Therapeutics, as Managing Director of Hatteras Discovery & Innovation (HDI).
Investment Strategy
Hatteras Venture Partners applies a thesis-driven approach, focusing on high-impact healthcare innovations with strong scientific foundations and clear commercialization potential.
The firm partners closely with entrepreneurs, offering not only capital but also strategic guidance, operational expertise, and access to a broad healthcare network.
Investments are aimed at achieving significant advances in human medicine, with an emphasis on long-term value creation.
Notable Investments
The firm’s portfolio includes:
Notable Exits
Hatteras has recorded 76 exits, including:
Members only
Leadership, investment strategy, notable investments and exits.
